Two-dose vaccines provide protection against lung disease in rhesus macaques one year after they were vaccinated as infants, a new study shows. The work, published in Science Translational Medicine Dec. 1, is a follow-up to a 2021 studying showing that the Moderna mRNA vaccine and a protein-based vaccine candidate containing an adjuvant, a substance that enhances immune responses, elicited durable neutralizing antibody responses to SARS-CoV-2 during infancy in preclinical research.
The co-senior authors of the paper are Kristina De Paris, professor of microbiology and immunology at the University of North Carolina at Chapel Hill; Sallie Permar, professor and chair of the Department of Pediatrics at Weill Cornell Medicine; and Koen K.A. Van Rompay, leader of the Infectious Disease Unit at the California National Primate Research at the University of California, Davis. Co-first authors are Emma C. Milligan at the Children’s Research Institute, UNC School of Medicine; and Katherine Olstad at the CNPRC.
To evaluate SARS-CoV-2 infant vaccination, the researchers immunized two groups of eight infant rhesus macaques at the CNPRC at 2 months of age and again four weeks later. Each animal received one of two vaccine types: a preclinical version of the Moderna mRNA vaccine or a vaccine combining a protein developed by the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID), with a potent adjuvant formulation. Consisting of 3M’s molecular adjuvant 3M-052 formulated in a squalene emulsion by the Access to Advanced Health Institute (AAHI), the adjuvant formulation stimulates immune responses by engaging receptors on immune cells.


.jpg)

_1.jpg)


_1.jpg)


.jpg)

